Trial Profile
An Open-label, Non-randomized Pharmacokinetic and Safety Study of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Renal Impairment.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Sep 2023
Price :
$35
*
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 08 Apr 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 08 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jan 2011 New trial record